Baird raised the firm’s price target on Quest Diagnostics (DGX) to $191 from $190 and keeps an Outperform rating on the shares. The firm ...

Quest Diagnostics (NYSE:DGX – Get Free Report) had its price objective lifted by equities researchers at Robert W. Baird from $190.00 to $191.00 in a note issued to investors on Thursday,Benzinga ...

With a market cap of $18.5 billion, Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic testing and ...

Jefferies maintained their Buy rating and raised their price target to $190, signaling confidence in the company's stock performance going forward. In other recent news, Quest Diagnostics reported ...

Piper Sandler reaffirmed a “neutral” rating and issued a $180.00 price target (up previously from $165.00) on shares of Quest Diagnostics in a research report on Monday, February 3rd. Mizuho ...

Analysts have set 12-month price targets for Quest Diagnostics, revealing an average target of $179.44, a high estimate of ...

Citi downgraded Quest Diagnostics (DGX) to Neutral from Buy with an unchanged price target of $185. The firm believes Quest is well positioned to capitalize on the on-going elevated utilization ...

Explore Quest Diagnostics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for DGX. Grail shares are trading higher Wednesday after the company announced a ...

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS ...

Top 5 Downgrades: Citi downgraded Quest Diagnostics (DGX) to Neutral from Buy with an unchanged price target of $185. The firm believes Quest is well positioned to capitalize on the on-going ...

With a market cap of $18.5 billion, Quest Diagnostics Incorporated (DGX ... it is trading below the mean price target of $178.25. On the date of publication, Sohini Mondal did not have ...